of TGFβ family to acquire a mesenchymal phenotype. 6, 7 As for EMT, it is demonstrated that EMT is activated via the TGFβ/Smad-dependent pathway in several cell lines. After binding with TGF-β1, TGF-β1 receptor leads Smad2 and Smad3 to phosphorylate. The phosphorylated Smad2 and Smad3 then combine with Smad4 to form a complex, which is translocated to the nucleus and promote the transcription of target genes, for example, the EMT related genes. Meanwhile, the Smad2/3/4-independent pathway also activates EMT. 8 Prostate transmembrane protein, androgen induced 1, PMEPA1
(also called TMEPA1, STAG1, ERG1.2 or N4WBP4), is located at chromosome 20q13. PMEPA1 expresses at the membrane of the cell and some subcellular organelles, such as endoplasmic reticulum and Golgi apparatus. PMEPA1 contains a transmembrane domain at the N-terminus and two PY motifs (PPxY) which interact with WW domain of the E3 ubiquitin ligase Nedd4. PMEPA1 was firstly found in prostate cancer as an androgen-induced gene. 9 However, PMEPA1 has duplicate roles in prostate cancer. In androgen receptor-positive prostate cancer cell, PMEPA1 promotes the proliferation. But in the androgen receptor-negative prostate cancer cells, PMEPA1 inhibits the proliferation by suppressing Smad3/4-c-Mycp21Cip1. 10 PMEPA1 also inhibits proliferation through the inhibition of NEDD and PTEN in prostate cancer. 11, 12 Moreover, PMEPA1
inhibits the bone metastasis by blocking the TGF-β and androgen signalling in prostate cancer. 13 In ovarian cancer, PMEPA1 has been reported to promote apoptosis. 14 However, PMEPA1 promotes the cancer progression in other solid cancer, 15 such as lung cancer, 16, 17 breast cancer, [18] [19] [20] gastric cancer 21 and ovarian cancer. 22 However, the anticancer role of PMEPA1 has been reported to promote apoptosis. 14 The difference might be resulted from tissue-specificity.
Different types of cancers exhibit different and special characteristic. As for PMEPA1, some studies have shown PMEAP1 inhibited proliferation through androgen receptor, 11 however, androgen receptor and the related signalling pathways have been activated in prostate cancer, but maybe not in lung cancer or breast, or colorectal cancer.
And the different role of PMEPA1 can be explained by the relationship of PMEPA1 and TGF-β pathways. PMEPA1 is induced by the TGF-β signalling, but meanwhile, it inhibits the phosphorylation of Smad2 and Smad3 to antagonize TGF-β signalling. 23 Considering the negative loop of PMEPA1 and TGF-β signalling, the phenotype of PMEPA1 in specific cancer needs deeper investigation.
PMEPA1 in CRC is associated with cancer poor prognosis.
Moreover, we built stable PMEPA1 overexpressed and PMEPA1-knockdown CRC cell lines to demonstrate that PMEPA1 promotes the cancer cell proliferation via inhibiting G1/S cell cycle arrest and inducing EMT related tumour metastasis. Besides, we investigated the regulation of PMEPA1 on TGF-β signalling. PMEPA1 blocked the canonical TGF-β signalling via dephosphorylating of Smad2 and Smad3. Interestingly, the BMP signalling, a non-canonical TGF-β signalling also promoted EMT and the pathway was activated by PMEAP1 which was BMP-depended in CRC. These new findings have thrown light on the role of PMEPA1 in colorectal cancer. 29 CRC expression and copy number profiling study from TCGA dataset were used to analysis association and survival.
| MATERIAL S AND ME THODS

| Public datasets analysis
| Pathway enrichment analysis
The correlated genes with PMEPA1 were screened in TCGA database and GSE35834 dataset by Pearson product-moment correlation analysis. A threshold of P < 0.05 and odds ratio >0.3 were used to screen the gene with significant correlations. The GSEA tool (http://software.broadinstitute.org/gsea/msigdb/) was used for pathways enrichment. 
| Clinical specimens
| Cell lines and cell culture
The human colon cancer cell lines SW620, HT29, HCT116, HCT 8 and HEK293t were purchased from the American Type Culture Collection (Manassas, VA, USA), and all the colon cancer cell above were cultured in RPMI 1640 medium (HyClone, Tauranga, New Zealand) with 10% foetal bovine serum (HyClone, Tauranga, New Zealand). HEK293T cell was cultured in DMEM high Glucose (HyClone, Tauranga, New Zealand) with foetal bovine serum (HyClone, Tauranga, New Zealand). All the cells are grown at 37℃ in an atmosphere of 95% and 5% CO 2 .
| DNA and siRNA constructs
The full CDS sequence of PMEPA1 was amplified and cloned into p3×FLAG-CMV-14 (Sigma). 
| Stable cell lines
All transfections were performed with Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer's instructions. HCT8
and HCT116 cell lines expressing PMEPA1 stably were obtained by transfection with pCMV-3 × flag vector containing PMEPA1
DNA and selected in 10μg/ml G418 for 2 weeks. SW620 and HT29
PMEPA1 knocked-down cell lines were built by the lentivirus which is produced by the HEK293T transfected with the pLKO vector containing sh-PMEPA1 and selected in 1 μg/mL puromycin for 2 weeks. 
| Cell proliferation assay
| Cell migration and invasion assay
The migration and invasion capacity of cells were tested by transwell migration and transwell invasion assays. 
| Western blot, immunohistochemistry and immunofluorescence
Western blot, immunohistochemistry and immunofluorescence were performed as previously. 30, 31 And the related antibodies were GAPDH was used as a loading control for Western blots. 
| Co-immunoprecipitation
Co
| RNA extraction and quantitative RT-PCR
Total RNA from the tissues were extracted using TRIZOL Reagent (Invitrogen). The RNA concentration was determined using UV spectrophotometry. cDNA was synthesized with PrimeScript ® RT regent kit (Takara Biotechnology, Dalian, China). RT-PCR was performed with Thunderbird SYBR Master Mix (Takara, Japan). The PCR was performed on a Real-time PCR Detection System (StepOnePlus, ABI) with the following cycles: 95°C for 1 minute, followed by 40 cycles of 95°C for 15 seconds, 60°C for 15 seconds and 72°C for 45 seconds to detect the target gene level and GAPDH gene levels.
GAPDH expression was used as an internal control. The 2 −ΔCT was calculated for every sample and normalized to GAPDH.
| Animal experiment
Male Serial sections of the embedded specimens were stained with haematoxylin and eosin (H&E) as conventionally conducted.
| Statistical analysis
The statistical package SPSS (version 20.0; IBM New York, NY, USA) was applied. Unpaired Student's t tests were used for normally distributed data and non-parametric Mann-Whitney U tests were used for non-normally distributed data to compare central tendencies. For results in CRC tissues, Relapse-free, metastasis-free or overall survival were compared between high and low PMEPA1 expression groups using median gene expression value as a bifurcating point. Correlations were analysed by the Spearman coefficient test. Significance was set at P < 0.05. Stata software was used to be a comprehensive evaluation that associated public datasets with clinical samples.
| RE SULTS
| PMEPA1 expresses higher in tumour and associated poor prognosis
Our previous gene expression microarray and bioinformatics works have shown the PMEPA1 expresses higher in tumour cells and tumour budding cells than that in stroma cells. 32 Tumour budding, occurring at the invasive front of cancer has a metastatic and stem-cell-like feature indicating a poor prognosis. Tumour budding is partly responsible for cancer metastasis, and its initiation is based on the epithelial-mesenchymal transition (EMT)
process. The expression of PMEPA1 was higher in tumour budding cells than tumour parenchyma cells and normal epithelial cells ( Figure 1A ). We then confirmed that mRNA expression of PMEPA1 was higher in tumour than normal tissue in TCGA and GEO database GDS2947 n = 32 P = 0.001 ( Figure 1B ), GSE31737 n = 40 P < 0.0001 ( Figure 1C ), GSE41329 n = 10 P = 0.0039 ( Figure 1D ), GSE32323 n = 17 P = 0.0002 ( Figure 1E ) and TCGA n = 32 P < 0.001 ( Figure 1F) , and all the data were from the paired samples. To identify the changes of PMEPA1 mRNA is related with copy number, we investigated the copy number of PMEPA1 in TCGA database, and found the mRNA level of PMEPA1 was increased in the copy number gained group ( Figure 1G ). We then analysed the relationship between copy number and mRNA expression of PMEPA1, which showed there was a significantly positive correlation between copy number and mRNA level of PMEPA1
( Figure 1H ). These data indicated that mRNA level of PMEPA1 is higher in CRC tumour tissue than normal tissue.
To explore the relation between PMEPA1 and the prognosis, we obtained a validation cohort from the GEO databases.
F I G U R E 1 Prostate transmembrane protein androgen induced 1 (PMEPA1) expresses higher in tumour and related with poor prognosis (A) the expression of PMEPA1 in normal epithelium cells, tumour parenchyma cells and tumour budding cells in colorectal cancer. B, GSD2941 showed that PMEPA1 mRNA expressed higher in tumour tissue when compared with paired adjacent normal tissue (P = 0.0001). C, GES31737 showed that PMEPA1 mRNA expressed higher in tumour tissue when compared with paired adjacent normal tissue (P < 0.0001). D, GSE41328 showed that PMEPA1 mRNA expressed higher in tumour tissue when compared with paired adjacent normal tissue (P = 0.0039). E, GSE32323 showed that PMEPA1 mRNA expressed higher in tumour tissue when compared with paired adjacent normal tissue (P = 0.0002). F, TCGA data showed that PMEPA1 mRNA expressed higher in tumour tissue when compared with paired adjacent normal tissue (P = 0.0039). G, TCGA data showed that mRNA level of PMEPA1 is higher in copy number gained group (focal CNV values larger than 0. The designations for levels of significance were used within this figure: *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant
Kaplan-Meier survival analysis was conducted to evaluate the prognostic value of the gene signature in three datasets retrieved from the GEO and TCGA database. The log-rank test results confirmed that the PMEPA1 was closely related to overall survival in three datasets TCGA n = 185 P = 0.022 ( Figure 1I ), GSE38832, n = 122, P = 0.026 ( Figure 1J ) and GSE17536, n = 55, P = 0.016 ( Figure 1K) ; and. Pearson correlation analysis confirmed that the expression of PMEPA1 was related to TNM stage in GSE38832
( Figure 1L ) and GSE 17537 ( Figure 1M ). PMEPA1 median centred ratio was related to recurrence in GSE38832, P = 0.03 ( Figure 1N ).
We also testified the samples from Sir Run Run Shaw Hospital and found mRNA level of PMEPA1 expressed higher in the tumour than normal tissue and the higher expression is related to the poor prognosis ( Figure 1O,P) .
Moreover, the results of TCGA database and Sir Run Run Shaw Hospital database were analysed by multivariate Cox proportional hazards regression model to find an independent prognostic value of PMEPA1 by adjusting location, differentiation, infiltrating depth, lymph node metastasis distant metastasis and TNM stage. After adjustment, PMEPA1 still showed a significant prognostic value.
( Tables 1 and 2 ).
| Knockdown of PMEPA1 inhibits proliferation and metastasis in colorectal cancer cells
To investigate the molecular role of PMEPA1 in colorectal cancer cells, first, we detected the mRNA and protein level in several colorectal cancer cell lines by RT-PCR and Western blot ( Figure S1A ).
Subsequently, we selected PMEPA1 higher expressed cell lines, HT29
and SW620, for building the stable PMEPA1 knockdown cell lines.
We then tested mRNA and protein level of PMEPA1 by RT-PCR and Figure 2H ). Immunofluorescence assay also validated that down-regulated PMEAP1 increased expression of E-cadherin but decreased fibronectin, a mesenchymal marker ( Figure 2I ). Taken together, the data shows PMEPA1 knockdown arrests cell at G1/S and inhibits CRC cell proliferation and PMEPA1 knockdown inhibits EMT and metastasis of CRC cells.
| PMEPA1 promotes proliferation and metastasis in colorectal cancer cells
As shown in Figure S1A , we chose PMEPA1-lower-expressed cell the expression of MMP9 and Snail ( Figure 3H ). Immunofluorescence assay also validated that PMEPA1 overexpression decreased the expression of E-cadherin, and increased fibronectin in HCT116 cells lines ( Figure 3I ). In order to confirm that the changed phenotypes are related to PMEPA1, we transfected siRNA-PMEPA1 and Negative control (siRNA-NC) into PMEPA1-overexpressed cell lines. As shown in Figure 3B , PMEPA1-siRNA inhibited the proliferation compared with siRNA-NC in PMEPA1 stable expressing HCT116 and HCT8 cell lines.
Transwell migration and invasion assays also indicated PMEPA-siRNA inhibited migration and invasion in the PMEPA-overexpressed cell lines ( Figure 3F ). As a result, PMEPA1 promotes proliferation via arresting G1/S cell cycle and enhances migration and invasion via EMT in vitro.
| PMEPA1 promotes proliferation and metastasis in vivo
To validate the role PMEPA1 in vivo, we subcutaneously inoculated control and PMEPA1-overexpressed HCT8 cells into male BALB/c group is larger than the control group. The weight of xenografts with PMEPA1 overexpressed were higher than the control xenografts which also confirms the proliferation induction of PMEPA1
( Figure 4A ). Furthermore, we inoculated control and PMEPA1-knockdown SW620 cell into male BALB/c nude mice, the continuous tumour volume measurement and the weight of the tumour indicated PMEPA1 knockdown reduces the proliferation in vivo ( Figure 4B ).
We then intravenously injected luciferase-labelled control and PMEPA1 knockdown SW620 cells into NOD/SCID mice and monitored metastasis with bioluminescent imaging. After 40 days, the whole-body luminescence signals in the PMEPA1 knockdown group were ~10-fold lower than the control group ( Figure 4C,D) . Moreover, the number of metastatic foci in the lung decreased significantly in the mice which were injected with PMEPA1 knockdown cells ( Figure 4E ). The results above indicate that PMEPA1 knockdown decreases the metastasis in mice.
Expression of E-cadherin was increased and the expression of Vimentin was decreased in the PMEPA1-knockdown xenografts ( Figure 4F ). However, in the PMEPA1-overexpressed xenograft, expression of E-cadherin was decreased and expression of MMP9 was increased ( Figure 4I ).
We then detected the mRNA levels of PMEPA1, E-cadherin, MMP9, Twist and Zeb1 of the xenograft. E-cadherin was decreased and MMP9, Twist and Zeb1 were increased in the PMEPA1-knockdown xenografts ( Figure 4G ). And E-cadherin was increased and MMP9, Twist and Zeb1 were decreased in PMEPA1-overexpressed The proliferation of HT29 and SW620 cells with PMEPA1 down-regulation was detected by CCK8 assay, plate clone assay and soft agar clone assay. E, Flow Cytometer detected the cell cycle and the proportion of each cell cycle. F, Migration and invasion assay were used for HT29 and SW620 cells with PMEPA1 down-regulation. The chambers were washed by 30% acetic and absorbance of washing solution was recorded at 570 mn for the quantification of the relative migration and invasion cells. G, Wound healing assay was used for the HT29 and SW620 cells with PMEPA1 down-regulation. And the length of the wound has been measured by Image J. H, Western blot detection of E-cadherin, MMP9, snail and PMEPA1 in HT29 and SW620 with PMEPA1 down-regulation. I, Immunofluorescence assay for expression of E-cadherin and Fibronectin in PMEPA1 down-regulated SW620 cells.The designations for levels of significance were used within this figure: *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant xenografts ( Figure 4J ). In the PMEPA1-knockdown group, protein levels protein E-cadherin was increased and the expression of Twist and Vimentin were decreased ( Figure 4H ). And protein levels of Ecadherin were decreased in the PMEPA1-overexpressed xenografts;
and the protein levels of MMP9 were decreased in the PMEAPA1-knockdown group ( Figure 4K ).
Moreover, we performed a correlation analysis between the expression of PMEPA1 and EMT markers. The results indicated a strong positive correlation between PMEPA1 and CHD2, Twist, FN1.
However, the result indicated PMEPA1 was negatively correlated with CDH1 (E-cadherin) ( Figure S1B ). Taken together, PMEPA1 promoted CRC proliferation, EMT and metastasis in vivo.
| PMEPA1 has dual role in TGF-β signalling
To explore the mechanism that PMEPA1 promotes EMT and metastasis. We analysed the public data from TCGA and GSE35834, and screened the gene expression profiles associated with F I G U R E 3 Prostate transmembrane protein androgen induced 1 (PMEPA1) promotes proliferation and metastasis in colorectal cancer cell lines (A) The efficiency of overexpressed PMEPA1 has been testified by qRT-PCR and Western blot in HCT116 and HCT8. And the efficiency of siRNA-PMEPA1 has been testified by qRT-PCR. B, The proliferation of HCT116 and HCT8 cells with PMEPA1 overexpressed and PMEPA1-overexpressed+siRNA-PMEPA1 was detected by CCK8 assay. The * markers in purple colours indicate the statistical analysis is between PMEPA1+NC and PMEPA1+siRNA; the * markers in red colours indicate the statistical analysis is between EV and PMEPA1. (C,D) The proliferation of HCT116 and HCT8 cells with PMEPA1 overexpressed was detected by plate clone assay and soft agar clone assay. E, Flow Cytometer detected the cell cycle and the proportion of each cell cycle. F, Migration and invasion assay have been used for HCT116 and HCT8 cells with PMEPA1 overexpressed and PMEPA1-overexpressed+siRNA-PMEPA1.The chambers were washed by 30% acetic and the absorbance of washing solution was recorded at 570 mn for the quantification of the relative migration and invasion cells. G, Wound healing assay has been used for the HCT116 and HCT8 cells with PMEPA1 overexpressed. And the length of the wound has been measured by Image J. The designations for levels of significance were used within this figure: *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant. H, Western blot detection of E-cadherin, MMP9, snail and PMEPA1 in HCT116 and HCT8 with PMEPA1 up-regulation. I, Immunofluorescence assay for expression of E-cadherin and Fibronectin in PMEPA1 up-regulated in HCT116 cells. The designations for levels of significance were used within this figure: *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant As we know, the role of PMEPA1 is complicated in TGF-β signalling. We then explored the relationship between PMEPA1
and TGF-Β signalling in CRC. We then tested phosphorylation of smad1/5, smad2 and smad3 after 3, 6 and 9 hours treated with 5 ng/mL TGF-β to find the optimal point of time when phosphorylation was activated ( Figure 5A ). As shown in Figure 5B To explore the role of BMP signalling in EMT induced by PMEPA1, we first verified whether PMEPA1 interacts with Smad1, a significant protein in BMP signalling. As shown in Figure S1C , the co-immunoprecipitation assay indicated no interaction between and Smad1. Moreover, to explore the role of BMP signalling pathway, we used siRNA-smad1 to decrease the expression of smad1 in the PMEPA1-overexpressed cells ( Figure S1E ,F). And the decreased mRNA level of E-cadherin caused by overexpressed PMEAP1 has been rescued by the siRNA-smad1 ( Figure S1G ). As shown in Figure   S1H , the decreased Smad1 inhibited the cell mobility induced by the PMEPA1. Taken together, PMEPA1 promotes migration via BMP signalling pathways.
F I G U R E 4 Prostate transmembrane protein androgen induced 1 (PMEPA1) promotes proliferation and metastasis in vivo (A) PMEPA1-overexpressed HCT8 cells and the control HCT8 cells (EV) have been subcutaneously inoculated into immune-deficient mice. And the volume of xenografts was recorded after injection. After 30 d, the weight of xenografts has been photographed and measured after killing the mice. B, PMEPA1-knockdown SW620 cells and control SW620 cells have been subcutaneously inoculated into immune-deficient mice. And the volume of xenografts was recorded after injection. After 26 d, the weight of xenografts has been photographed and measured after killing the mice. C, Representative images of luciferase signals and (D) quantification of photon flux for metastasis by tail-vein injection of SW620-SC and SW620-shRNA PMEPA1 cells in immune-deficient mice. E, H&E staining for pulmonary metastatic foci from SW620-SC and SW620-shRNA PMEPA1cells. And the foci in lungs of SW620-SC and SW620-shRNA PMEPA1 groups were counted. F, Immunohistochemistry detection for PMEPA1, E-cadherin, Vimentin in SW620-SC and SW620-shRNA PMEPA1 xenografts. G, qRTPCR dectection for PMEPA1, E-cadherin, MMP9, Twist and Zeb1vimentin in SW620-SC and SW620-shRNA PMEPA1 xenografts. H, Western blot detection for E-cadherin, vimentin, PMEPA1 and Twist in SW620-SC and SW620-shRNA PMEPA1 xenografts. I, Immunohistochemistry detection for PMEPA1, E-cadherin, MMP9in HCT8-EV and HCT8-PMEPA1 xenografts. J, qRT-PCR dectection for PMEPA1, E-cadherin, MMP9, Twist and Zeb1vimentin in HCT8-EV and HCT8-PMEPA1 xenografts. (K) Western blot detection for E-cadherin, vimentin and PMEPA1 in HCT8-EV and HCT8-PMEPA1 xenografts. The designations for levels of significance were used within this figure: *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant also suppresses prostate cancer metastases to bone by inhibition of TGF-β signalling and interfering the formation of complex of Smad2/3 and Smad4. 13 In this study, the experiments data in vivo and in vitro showed PMEPA1 promoted migration and invasion as a pro-metastatic molecule. We speculated that the tissue or organ specific expression of PMEPA1 might cause the contradictory phenotype in colorectal cancer. In some types of cancer, PMEPA1
| D ISCUSS I ON
has been reported to promote cancer metastasis. In breast cancer, PMEPA1 reduces PTEN and promotes non-canonical PI3K/ Akt signalling to promote cancer progression. 33 In prostate cancer, PMEPA1 inhibits Smad3/4-cmyc-p21Cip1 signalling pathway to promote prostate cancer cell proliferation. 10 In lung cancer, PMEPA1
regulates ROS and IRS-1 signalling and induces EMT to promote metastasis. 35 Together, PMEPA1 could be considered as a versatile molecule, which functions the complex roles in different types of cancer.
As we know, TGF-β is a classical inducer of EMT to drive tumour cell migration, invasion, and metastasis in many carcinomas. 36 As a TGF-β-inducible gene, PMEPA1 regulated multiple biological process in several types of cancer. 16, 20, 37 Some reports showed PMEPA1 accelerates the metastasis and EMT through TGF-β signalling. 35 Nevertheless, we demonstrated PMEPA1 promoted migration and invasion, and induced EMT in CRC by activating the BMP signalling pathway with phosphorylation of Smad1 and Smad5. Previous reports have indicated the role of BMP signalling pathways in EMT. In colorectal cancer, BMP-2, an inducer of BMP signalling, induces EMT and drug resistance. 38 BMP-2 also induces BMP signalling and EMT in pancreatic cancer. 39 The agonists of BMP-2 and BMP-7 also block the BMP signal, and inhibit EMT and invasion in melanoma cells. 40 PMEPA1, which activates BMP signalling pathway like BMP-2 and BMP7, might have the potential to be a novel target for molecular agonists design. However, the detailed mechanism of PMEPA1 activating BMP signalling remained to further study.
In conclusion, we revealed that PMEPA1 promoted EMT-mediated metastasis through activating TGF-β non-canonical signalling cascade.
Although the conclusion needs more clinical studies to valid, PMEPA1 might has the potential to serve as a meaningful biomarker for high-risk CRC or to serve as a therapeutic target for intervene colorectal cancer. 
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